The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
Big Pharma needs an antitrust antidote.
The Federal Trade Commission and its hard-nosed chair Lina Khan have struck again, this time filing a lawsuit in federal court on Tuesday to halt biotech giant Amgen's $28 billion blockbuster acquisition of Horizon Therapeutics. Consider it a black box warning for the industry's M business model in a newer, tougher antitrust world.
Source Fool.com
Amgen Inc. Aktie
310,70 €
0,91 %
Überwältigende Zustimmung für Amgen Inc. mit ausschließlich Buy-Einschätzungen.
Trotz eines Kursziels von 304 €, das unter 310.7 € liegt, ergibt sich für Amgen Inc. ein negatives Potenzial von -2.16%.
